Clinical Trials

The Doctors at the Hematology\Oncology Clinic have more than 20 years of experience in conducting and treating patients on national clinical trials.

Because of their dedication to cancer treatment they are able to offer patients access to the latest treatment options available..

BREAST – ADJUVANT

NSABP-B-44-I :  BETH     
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

NSABP B-43 
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with
HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

NSABP B-46-I
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative,
HER2-Negative Breast Cancer

E5103
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

TAILOR Rx / PACCT 1    
Trial Assigning Individualized Options for Treatment - Program for the Assessment of Clinical Cancer Tests (PACCT-1) “The TAILORx Trial”

SCRI BRE 145
A Randomized Trial of Ixempra™ vs. Taxol in Adjuvant Therapy of Triple-Negative
Breast Cancer (TITAN)

Wyeth: (3144A2-3004-WW)
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer

S0221 
A Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node Positive or High-Risk Node-Negative Breast Cancer

BREAST –METASTATIC

Bipar (Closing 02/28/2010)
A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer 

CRAD001Y2301
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in 
Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive, Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole

CALGB 40302
Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: a Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer

GI – ADJUVANT COLON/RECTAL

E5202
 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU,  Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for   Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers 

GI – METASTATIC  COLON/RECTUM

CALGB 80405
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5- FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

VELOUR EFC10262:  Met CRC 2nd line (NSABP/Sanofi Aventis)
A Multinational, Randomized, Double-blind Study Comparing Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan/5-FU Combination (FOLFIRI) after failure of an Oxaliplatin Based Regimen.

HEAD & NECK

E1305: A Phase III Randomized Trial of Chemotherapy with or without
Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

LUNG – 1st line

S0819, "A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

CALGB 30607 
Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

SCRI  LUN 142 – NSCLC 
A Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients with Resected Non-Small Cell Lung Cancer- Stage IB-IIIA  

E1505 - NSCLC
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)

LUNG 2nd Line

SCRI LUN 162
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients
with Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib (WIRB)

SCRI LUN 199
A Phase II Trial of Amrubicin and Carboplatin with Pegfilgrastim in Patients with Extensive-Stage Small Cell Lung Cancer

LYMPHOMA

SCRI LYM 66
Phase II TRIAL OF BENDAMUSTINE, BORTEZOMIB, AND RITUXIMAB In Patients with Previously Low Grade Lympnoma.

SCRI  LYM  37 (relapsed)
A Phase II Trial with Rituximab ± Bevacizumab in the Treatment of Patients with Follicular Non-Hodgkin’s Lymphoma: A Randomized

MELANOMA

ECOG 1697
Phase II Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2bN0, T3a- b No,T4a-bN0 and T1-4,N1a,2a (Microscopic) Melanoma. 
     
S0826  A Phase II Study of SCH 727965 in Stage IV Melanoma .

PANCREATIC

1st Line Pancreatic   (Abraxis)
A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine  Alone in Patients with Metastatic Adenocarcinoma of the Pancreas.

PROSTATE

E3805: CHAARTED:  ChemHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer

CALGB 90202:  A Randomized, Double-Blind, Placebo-Controlled Phase III     Study  Of Early vs Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone.

RENAL

E2805 ASSURE
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

E2804 The BeST Trial 
A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combinatiion 
Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temirolimus in Advanced Renal Cell Carcinoma

SCRI GU 49
A Phase II Study of LBH589 in the Treatment of Patients with Refractory Clear Cell Renal Carcinoma (WIRB)

UNKOWN PRIMARY

SCRI UNK PRI 20   
A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling
Diagnosis of Patients with Carcinoma of Unknown Primary Site.

Choosing to participate in a clinical trial is an important personal decision. Our physicians and staff are available to assist you in making that decision.

For more information about the clinical trials available you may call the research office at (225) 763-4815.